"Bear what, if anything, will the holders OG the spun off units receive?"

Yet to be determined. Resverlogix revenue would bring money to Zenith Capital Corp (ZCC), who holds the Royalty Preferred Shares. Zenith Epigenetics Ltd (ZEL) is a wholly owned subsidiary of ZCC. ZEL is the clinical/science side with all of the Zenith intellectual property and compounds. Those who received spin off units hold shares of ZCC. Lots of compounds owned by both Resverlogix and Zenith. Things could get spun off or sold off or licensed like peeling an onion or like a Star Factory.  Either company could commercialize compound(s) independently or with a partner. Resverlogix revenue would benefit ZCC, but no guarantee any of this would flow to shareholders via dividends. Lots of moving parts and potential scenarios. First things first....... successful clinical trials!

BearDownAZ